A Study to Assess the Safety, Tolerability and Pharmacokinetics of ASP015K in Healthy Subjects
- Conditions
- Pharmacokinetics of ASP015KHealthy Volunteers
- Interventions
- Drug: Placebo
- First Posted Date
- 2014-05-19
- Last Posted Date
- 2014-06-04
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 16
- Registration Number
- NCT02141425
- Locations
- 🇺🇸
California Clinical Trials Medical Group/Parexel, Glendale, California, United States
A Study to Evaluate Tolerability and Participants Preference Between Mirabegron and Tolterodine Extended Release (ER) in Participants With Overactive Bladder (OAB)
- First Posted Date
- 2014-05-15
- Last Posted Date
- 2020-02-26
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 376
- Registration Number
- NCT02138747
- Locations
- 🇺🇸
Site US10002 Urology Centers of Alabama, Homewood, Alabama, United States
🇺🇸Site US10004 Alaska Clinical Research Center, LLC, Anchorage, Alaska, United States
🇺🇸Site US10001 Urological Associates of Southern Arizona, Tucson, Arizona, United States
A Study to Evaluate the Effect of Multiple Doses of Isavuconazole on the Pharmacokinetics of Repaglinide and Caffeine
- Conditions
- Pharmacokinetics of RepaglinidePharmacokinetics of CaffeineHealthy Subjects
- Interventions
- First Posted Date
- 2014-05-01
- Last Posted Date
- 2014-05-01
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT02128321
- Locations
- 🇺🇸
Parexel Early Phase Clinical Unit, Baltimore, Maryland, United States
A Study to Evaluate the Effect of Multiple Doses of Esomeprazole on the Pharmacokinetics of Isavuconazole
- Conditions
- Pharmacokinetics of IsavuconazoleHealthy Subjects
- Interventions
- First Posted Date
- 2014-05-01
- Last Posted Date
- 2014-05-01
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT02128893
- Locations
- 🇺🇸
Parexel Early Phase Clinical Unit, Baltimore, Maryland, United States
A Dose Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of ASP2408 Following Single Intravenous Doses in Healthy Subjects
- Conditions
- Healthy SubjectsPharmacokinetics of ASP2408
- Interventions
- Drug: Placebo
- First Posted Date
- 2014-04-29
- Last Posted Date
- 2014-04-29
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 65
- Registration Number
- NCT02125435
- Locations
- 🇺🇸
PAREXEL International, Baltimore, Maryland, United States
A Dose Escalation Study of ASP8273 in Subjects With Non-Small-Cell Lung Cancer (NSCLC) Who Have Epidermal Growth Factor Receptor (EGFR) Mutations
- Conditions
- Non-Small-Cell Lung Cancer (NSCLC)Epidermal Growth Factor Receptor Mutations
- Interventions
- First Posted Date
- 2014-04-15
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 133
- Registration Number
- NCT02113813
- Locations
- 🇺🇸
Site US10010, Washington, District of Columbia, United States
🇺🇸Site US10006, Baltimore, Maryland, United States
🇺🇸Site US10012, Boston, Massachusetts, United States
A Study to Evaluate the Effect of Verapamil on the Pharmacokinetics of ASP015K in Healthy Adult Subjects
- Conditions
- Healthy SubjectsPharmacokinetics of ASP015K
- Interventions
- First Posted Date
- 2014-04-11
- Last Posted Date
- 2014-04-11
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT02111317
- Locations
- 🇺🇸
PAREXEL, Glendale, California, United States
An Evaluation of a Cytomegalovirus (CMV) Vaccine (ASP0113) in CMV-Seropositive and CMV-Seronegative Healthy Subjects and CMV-Seronegative Dialysis Patients
- Conditions
- DialysisHealthy SubjectsCytomegalovirus Infection
- Interventions
- Drug: Placebo
- First Posted Date
- 2014-04-03
- Last Posted Date
- 2024-10-17
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 48
- Registration Number
- NCT02103426
- Locations
- 🇺🇸
Site US10009, Los Angeles, California, United States
🇺🇸Site US10003, Orlando, Florida, United States
🇺🇸Site US10001, Baltimore, Maryland, United States
A Study to Assess the Efficacy and Safety of Enzalutamide With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2 Positive (HER2+), Androgen Receptor Positive (AR+) Metastatic or Locally Advanced Breast Cancer
- Conditions
- HER2 AmplifiedHuman Epidermal Growth Factor Receptor 2 (HER2)Advanced Breast Cancer
- Interventions
- First Posted Date
- 2014-03-19
- Last Posted Date
- 2025-04-04
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 103
- Registration Number
- NCT02091960
- Locations
- 🇺🇸
Site US10051, Anaheim, California, United States
🇺🇸Site US10028, Los Angeles, California, United States
🇺🇸Site US10035, San Francisco, California, United States
A Study of Escalating Doses of ASG-22CE Given as Monotherapy in Subjects With Metastatic Urothelial Cancer and Other Malignant Solid Tumors That Express Nectin-4
- Conditions
- Metastatic Urothelial Cancer and Other Malignant Solid Tumors
- Interventions
- Drug: enfortumab vedotin
- First Posted Date
- 2014-03-19
- Last Posted Date
- 2024-11-01
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 213
- Registration Number
- NCT02091999
- Locations
- 🇺🇸
Site US00012, Los Angeles, California, United States
🇺🇸Site US00019, Stanford, California, United States
🇺🇸Site US00017, Aurora, Colorado, United States